Drug intelligence / Profile preview

EVOLVE109

Development stage: Preclinical
Lead developer: EvolveImmune Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

EVOLVE109 is a preclinical-stage, platform-derived multispecific T-cell engager being developed by EvolveImmune in collaboration with AbbVie. The therapeutic candidate is designed using EvolveImmune's proprietary EVOLVE platform, which integrates CD2 co-stimulation alongside T-cell receptor engagement to bypass low tumor immunogenicity and enhance tumor-killing capabilities. This approach aims to overcome resistance to current immunotherapies in solid and hematologic malignancies. EVOLVE109 is currently in the lead optimization phase of development.

Targets

CD2 (T-cell Surface Antigen CD2)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on EVOLVE109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVOLVE109.

Explore the full profile